大环内酯类药物在治疗婴幼儿喘息性疾病中的应用  

Macrolides for treatment of asthmatic disease in infants

作　　者：王彦波[1] 杨海燕[1] 汤璘珊[1] 

机构地区：[1]蚌埠医学院第一附属医院儿科,安徽蚌埠233004

出　　处：《蚌埠医学院学报》2013年第6期713-715,共3页Journal of Bengbu Medical College

摘　　要：目的:观察大环内酯类药物治疗婴幼儿喘息性疾病的效果。方法:将150例婴幼儿喘息性疾病分为2组,治疗组80例用大环内酯类抗生素治疗,对照组70例用β-内酰胺类抗生素治疗,比较分析2组疗效。结果:治疗组总有效率为86.25%,高于对照组的70.00%(P<0.05)。治疗组临床症状缓解时间及住院时间均小于对照组(P<0.05～P<0.01)。所有病例随访1年,治疗组再发率40.00%,对照组再发率58.57%,差异有统计学意义(P<0.05)。结论:大环内酯类药物治疗小儿喘息性疾病有良好效果,且愈后较理想,值得推广应用。Objective：To observe the effect of macrolides in treatment of infant asthmatic respiratory diseases. Methods：One hundred and fifty infants with asthmatic diseases were randomly divided into two groups. The 80 cases in the treatment group were administered macrolides antibiotics and the 70 cases in control group received [3-1actam antibiotics. The curative effects were compared between the two groups. Results：The total effective rate was 86.25% in the treatment group and 70.00% in the control（P 〈 0.05 ）. The symptom release time and length of hospital stay in the treatment group were less than those of the control（ P 〈 0.05 - P 〈 0.01 ）. All the patients were followed up for one year. The recurrence rate was 40.00% in the treatment group and 58.57% in the control group, the difference was statistically significant（ P 〈 0.05 ）. Conclusions ： Macrolides is effective on infant asthmatic respiratory diseases and the prognosis is satisfactory. It is worth widely popularizing.

关 键 词：呼吸道疾病 喘息 大环内酯类药物 婴幼儿 

分 类 号：R725.6[医药卫生—儿科]